期刊
FUTURE CARDIOLOGY
卷 11, 期 5, 页码 547-564出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fca.15.50
关键词
antiplatelet therapy; platelet aggregation; protease-activated receptor 1; thrombin; vorapaxar
资金
- Sanofi
- Eli Lilly
- Daiichi-Sankyo
- The Medicines Company
- AstraZeneca
- Merck
- Abbott Vascular
- PLx Pharma
- Glaxo-Smith-Kline
- Janssen Pharmaceuticals, Inc.
- Osprey Medical, Inc.
- Novartis
- CSL Behring
- Gilead
Oral antiplatelet therapies for secondary prevention of ischemic recurrences in patients with atherosclerotic disease manifestations include aspirin and P2Y12 receptor antagonists. Despite the use of these therapies, patients remain at risk for recurrent ischemic events, which may be attributed to other platelet signaling pathways which continue to be activated. More intense antithrombotic strategies have been investigated, including identifying additional targets to modulate platelet activation. Among these, thrombin-mediated platelet activation through PAR-1 has been subject to broad clinical investigation. Vorapaxar is the only PAR-1 receptor antagonists that completed large-scale clinical investigations and is approved for clinical use. This manuscript provides an overview of the pharmacology and clinical trial development of vorapaxar as well as its role in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据